Table 1.
Study Participants
| Age, years | Gravity/parity | Phase (d) | rASRM stage | Symptoms | Lesion locations | DIE | Study |
|---|---|---|---|---|---|---|---|
| 27 | 0/0 | Prolif (8) | IV | Pain/infertility | Sig nodule | Yes | IHC |
| 31 | 1/1 | Prolif (1) | IV | Pain/infertility | Vag nodule | Yes | IHC |
| 33 | 0/0 | Prolif (11) | IV | Pain/infertility | Vag nodule | Yes | IHC |
| 31 | 0/0 | Prolif (9) | IV | Pain/infertility | Sig nodule | Yes | IHC/CX |
| 31 | 2/1 | Prolif (6) | III | Pain | Perit/L ov | No | CX |
| 36 | 0/0 | Prolif (10) | II | Pain | L tube, ov | No | CX |
| 35 | 0/0 | Prolif (8) | IV | Pain/infertility | R ov, vag nodule | Yes | CX |
| 23 | 0/0 | Prolif (5) | II | Pain/infertility | Perit/R ov | No | CX |
CX, cell culture; d, cycle day; DIE, deep infiltrating endometriosis; IHC, immunohistochemistry; L, left; ov, ovary; perit, peritoneal implant; prolif, proliferative phase of menstrual cycle; R, right; rASRM, revised American Society for Reproductive Medicine endometriosis stage; sig, sigmoid; study, protocol; vag, vaginal.